Drug Profile
Research programme: progesterone antagonists - Johnson & Johnson
Alternative Names: JNJ-1250132; JNJ-38539449Latest Information Update: 16 Jul 2016
Price :
$50
*
At a glance
- Originator Johnson & Johnson Pharmaceutical Research & Development
- Class Cyclopentanes; Dimethylamines
- Mechanism of Action Progesterone receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Breast cancer
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in Breast-cancer in USA
- 03 Sep 2007 Data presented at the 234th American Chemical Society National Meeting (234th-ACS-2007) added to the pharmacokinetics section
- 01 Jul 2005 Preclinical trials in Breast cancer in USA (unspecified route)